胃早期癌和癌前病变的基因表达谱和组织蛋白表达研究
|
摘要
背景：胃早期癌和癌前病变多无明显的临床症状,胃癌及癌前病变相关的临床和生物学研究将有助于改善病人整体预后。目的：本研究从胃低级别上皮内瘤变、高级别上皮内瘤变和早期胃癌的表达谱特征入手,寻找它们的生物学联系和差异,分析胃癌变早期的分子功能变化、筛选胃早期癌变可能起关键作用的基因、并在组织蛋白水平探索其诊断标志物价值。将有助于揭示胃早期癌变的相关生物学事件,为分子诊断和标志物研究提供线索,为临床处理提供生物学依据。方法：本研究首先通过全基因表达谱芯片实验对19例胃低级别上皮内瘤变(LGIN)、20例胃高级别上皮内瘤变(HGIN)、19例早期胃癌(EGC)和19例慢性胃炎的组织mRNA表达特征进行分析,运用G0富集分析探索胃癌变早期的生物学规律,并筛选出重要的生物学功能及相关基因,GOS2基因和OSM基因；其次通过实时定量PCR实验,对GOS2基因和OSM基因在独立的26例LGIN、15例HGIN、14例EGC和20例慢性胃炎组织样本中的mRNA表达水平进行验证；同时,通过免疫组织化学染色实验,在65处慢性胃炎,45处肠上皮化生,24处低级别上皮内瘤变、46处高级别上皮内瘤变、33处早期胃癌和18处进展期胃癌组织中,检测GOS2基因和OSM基因的蛋白表达水平。结果：LGIN与HGIN、 LGIN与胃早期癌mRNA表达特征的差异显著,生物学功能主要为代谢、防御反应和NF-kB通路相关。HGIN和胃早期癌mRNA表达特征的差异并不显著,与免疫功能关系密切。GOS2和OSM基因的组织mRNA和蛋白表达水平,在HGIN和EGC中呈明显的高表达水平；而随着病变发展,进展期胃癌组织中的蛋白表达水平下降。结论：LGIN和HGIN基因表达特征的差异显著；相比于LGIN, HGIN和胃早期癌间的生物学联系更紧密。在胃癌变早期,起重要作用的基因随着LGIN→HGIN→EGC进展,表达水平不断升高。在肿瘤发生、发展中起重要作用的能量代谢、免疫反应、NF-kB信号通路,可能是胃癌变早期的重要生物学事件。筛选出的基因在胃癌变早期的表达改变显著,可能具一定分子诊断价值。
Background:Unlike advanced-stage patients, patients with early-stage gastric adenocarcinoma(EGC) and precancerous lesions usually have no symptoms. It is important to understand more about EGC and precancerous lesions both clinically and biologically to improve the overall survival of patients with gastric carcinoma. Objectives:To explore the biological similarities and differences among high-and low-grade intraepithelial neoplasia(HGIN and LGIN, respectively), and EGC in detail, this study characterized their whole genome expression profiling to analyze the molecular and functional changes and discover related important genes in gastric early carcinogenesis. Together with the following evaluating of protein expression in tissues, this study would be a benefit for revealing of the early events in gastric carcinogenesis and provide some clue to related biomarker research. Methods:Gene expression profiling was performed on19LGIN,20HGIN,19EGC, and19gastritis tissue samples using microarrays. A GO(gene ontology) enrichment analysis was performed to explore the molecular distinction and functional correlation among these tissues. The differentially expressed genes, GO/G1switch2(GOS2) and Oncostatin M(OSM) were identified and their mRNA expression were validated using a real-time TaqMan(?) PCR assay with another group of independent tissue samples, including26LGIN,15HGIN,14EGC, and20gastritis. Furthermore, immunohistochemical(IHC) staining was used to detect GOS2and OSM expression in65cases chronic gastritis,45cases gastric intestinal metaplasia(IM),24cases LGIN,46cases HGIN,33cases EGC and18cases advanced-stage gastric adenocarcinoma(AGC). Results:The gene expression patterns of the LGIN and HGIN tissues and between LGIN and EGC were distinct. The related biological function were in the category of metabolism, defense response, and NF-kB cascade. The molecular differences between HGIN and EGC are not significant, which were mainly focused on the immune response. The mRNA expression and tissue expression after IHC staining of GOS2and OSM were relatively increased in HGIN and EGC. Conclusions:HGIN and LGIN are biologically distinct. Compared with LGIN, the biological similarities between HGIN and EGC were prominent. The overexpression of GOS2and OSM were validated as the neoplasia progressed from LGIN to HGIN, and then EGC. Alterations of metabolism and the immune response contribute to the malignant progression of gastric neoplasia, and maybe early events in gastric carcinogenesis.
Background:Unlike advanced-stage patients, patients with early-stage gastric adenocarcinoma(EGC) and precancerous lesions usually have no symptoms. It is important to understand more about EGC and precancerous lesions both clinically and biologically to improve the overall survival of patients with gastric carcinoma. Objectives:To explore the biological similarities and differences among high-and low-grade intraepithelial neoplasia(HGIN and LGIN, respectively), and EGC in detail, this study characterized their whole genome expression profiling to analyze the molecular and functional changes and discover related important genes in gastric early carcinogenesis. Together with the following evaluating of protein expression in tissues, this study would be a benefit for revealing of the early events in gastric carcinogenesis and provide some clue to related biomarker research. Methods:Gene expression profiling was performed on19LGIN,20HGIN,19EGC, and19gastritis tissue samples using microarrays. A GO(gene ontology) enrichment analysis was performed to explore the molecular distinction and functional correlation among these tissues. The differentially expressed genes, GO/G1switch2(GOS2) and Oncostatin M(OSM) were identified and their mRNA expression were validated using a real-time TaqMan(?) PCR assay with another group of independent tissue samples, including26LGIN,15HGIN,14EGC, and20gastritis. Furthermore, immunohistochemical(IHC) staining was used to detect GOS2and OSM expression in65cases chronic gastritis,45cases gastric intestinal metaplasia(IM),24cases LGIN,46cases HGIN,33cases EGC and18cases advanced-stage gastric adenocarcinoma(AGC). Results:The gene expression patterns of the LGIN and HGIN tissues and between LGIN and EGC were distinct. The related biological function were in the category of metabolism, defense response, and NF-kB cascade. The molecular differences between HGIN and EGC are not significant, which were mainly focused on the immune response. The mRNA expression and tissue expression after IHC staining of GOS2and OSM were relatively increased in HGIN and EGC. Conclusions:HGIN and LGIN are biologically distinct. Compared with LGIN, the biological similarities between HGIN and EGC were prominent. The overexpression of GOS2and OSM were validated as the neoplasia progressed from LGIN to HGIN, and then EGC. Alterations of metabolism and the immune response contribute to the malignant progression of gastric neoplasia, and maybe early events in gastric carcinogenesis.
引文
[1]Ferlay J, Shin H, Bray F, et al. Globocan 2008, cancer incidence and mortality worldwide:Iarc cancerbase no.10. Lyon, france: International agency for research on cancer; 2010 [J]. globocan iarc fr [verified February 2012],2010.
[2]Dai M, Ren J, Li N, et al. [estimation and prediction on cancer related incidence and mortality in china,2008] [J]. Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi,2012,33(1):57-61.
[3]Ohta H, Noguchi Y, Takagi K, et al. Early gastric carcinoma with special reference to macroscopic classification [J]. Cancer, 1987,60 (5):1099-1106.
[4]Lazar D, Taban S, Dema A, et al. Gastric cancer:The correlation between the clinicopathological factors and patients'survival (i) [J]. Rom J Morphol Embryol,2009,50(1):41-50.
[5]Bosman FT, Carneiro F, Hruban RH, et al. Who classification of tumours of the digestive system [M]. World Health Organization,2010.
[6]Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (maps):Guideline from the european society of gastrointestinal endoscopy (esge), european helicobacter study group (ehsg), european society of pathology (esp), and the sociedade portuguesa de endoscopia digestiva (sped) [J]. Endoscopy,2012,44 (1):74-94.
[7]Shen L, Shan Y-S, Hu H-M, et al. Management of gastric cancer in asia:Resource-stratified guidelines [J]. The Lancet Oncology, 2013,14(12):e535-e547.
[8]Correa P. Human gastric carcinogenesis-a multistep and multifactorial process-1st american-cancer-society award lecture on cancer-epidemiology and prevention [J]. Cancer research, 1992,52 (24):6735-6740.
[9]Meining A, Morgner A, Miehlke S, et al. Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach:A reality or merely an hypothesis? [J]. Best Pract Res Cl Ga,2001,15(6):983-998.
[10]de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions:A nationwide cohort study in the netherlands [J]. Gastroenterology,2008,134(4):945-952.
[11]Uchida M, Tsukamoto Y, Uchida T, et al. Genomic profiling of gastric carcinoma in situ and adenomas by array-based comparative genomic hybridization [J]. The Journal of pathology,2010,221(1):96-105.
[12]Dixon MF. Gastrointestinal epithelial neoplasia:Vienna revisited [J]. Gut,2002,51(1):130-131.
[13]Rugge M, Capelle LG, Cappellesso R, et al. Precancerous lesions in the stomach:From biology to clinical patient management [J]. Best practice& research Clinical gastroenterology,2013,27(2):205-223.
[14]Hong L, Li S, Liu L, et al. The value of mg7-ag and cox-2 for predicting malignancy in gastric precancerous lesions [J]. Cell biology international,2010,34(9):873-876.
[15]Vecchi M, Nuciforo P, Romagnoli S, et al. Gene expression analysis of early and advanced gastric cancers [J]. Oncogene, 2007,26 (29):4284-4294.
[16]Li ML, Zhang JC, Li SG, et al. Characteristic gene expression profiles in the progression from normal gastric epithelial cells to moderate gastric epithelial dysplasia and to gastric cancer [J]. Chinese medical journal,2012,125(10):1777-1783.
[17]Association WM. World medical association declaration of helsinki ethical principles for medical research involving human subjects [J]. JAMA:the journal of the American Medical Association,2013.
[18]Yamada T, Lee P-H, Burns A, et al. G0s2, an early response gene, regulates quiescence in naive t cells [J]. The Journal of Immunology, 2011,186(104.110.
[19]Heckmann BL, Zhang X, Xie X, et al. The g0/g1 switch gene 2 (g0s2):Regulating metabolism and beyond [J]. Biochimica et biophysica acta,2013,1831 (2):276-281.
[20]Welch C, Santra MK, El-Assaad W, et al. Identification of a protein, g0s2, that lacks bcl-2 homology domains and interacts with and antagonizes bcl-2 [J]. Cancer research,2009,69(17):6782-6789.
[21]Heinrich P, Behrmann I, Haan S, et al. Principles of interleukin (il)-6-type cytokine signalling and its regulation [J]. Biochem J, 2003,374(1-20.
[22]Hanahan D, Weinberg RA. Hallmarks of cancer:The next generation [J]. Cell,2011,144(5):646-674.
[23]Jones RG, Thompson CB. Tumor suppressors and cell metabolism:A recipe for cancer growth [J]. Genes& development,2009,23(5):537-548.
[24]Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism [J]. Nature reviews Cancer,2011,11(2):85-95.
[25]Santos CR, Schulze A. Lipid metabolism in cancer [J]. The FEBS journal,2012,279(15):2610-2623.
[26]Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism:Current perspectives and future directions [J]. Cell death& disease, 2012,3(e248.
[27]Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting:Integrating immunity's roles in cancer suppression and promotion [J]. Science, 2011,331 (6024):1565-1570.
[28]Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer [J]. Annual review of immunology, 2011,29(235-271.
[29]Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation:A magic bullet? [J]. Science,2013,339(6117):286-291.
[30]Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer [J]. Cell,2010,140(6):883-899.
[31]Li Q, Verma IM. Nf-kappab regulation in the immune system [J]. Nature reviews Immunology,2002,2(10):725-734.
[32]Karin M, Greten FR. Nf-kappab:Linking inflammation and immunity to cancer development and progression [J]. Nature reviews Immunology, 2005,5(10):749-759.
[33]Naugler WE, Karin M. Nf-kappab and cancer-identifying targets and mechanisms [J]. Current opinion in genetics& development, 2008,18(1):19-26.
[34]Karin M. Nuclear factor-kappab in cancer development and progression [J]. Nature,2006,441(7092):431-436.
[35]Fucci A, Colangelo T, Votino C, et al. The role of peroxisome proliferator-activated receptors in the esophageal, gastric, and colorectal cancer [J]. PPAR research,2012,2012(242498.
[36]Zandbergen F, Mandard S, Escher P, et al. The g0/g1 switch gene 2 is a novel ppar target gene [J]. The Biochemical journal,2005,392(Pt 2)-.313-324.
[37]Kusakabe M, Kutomi T, Watanabe K, et al. Identification of g0s2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches [J]. International journal of cancer Journal international du cancer,2010,126(8):1895-1902.
[38]Nobuhiko Takahashi TO, Wataru Motomura, Yoshinori Fujimoto, Isao Kawabata, Yutaka Kohgo. Activation of ppar inhibits cell growth and induces apoptosis in human gastric cancer cells [J]. FEBS Letters, 1999,455(135-139.
[39]Schweiger M, Paar M, Eder C, et al. G0/g1 switch gene-2 regulates human adipocyte lipolysis by affecting activity and localization of adipose triglyceride lipase [J]. Journal of lipid research, 2012,53(11):2307-2317.
[40]Kusakabe M, Watanabe K, Emoto N, et al. Impact of DNA demethylation of the g0s2 gene on the transcription of g0s2 in squamous lung cancer cell lines with or without nuclear receptor agonists [J]. Biochemical and biophysical research communications,2009,390(4):1283-1287.
[41]Das SK, Eder S, Schauer S, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia [J]. Science, 2011,333(6039):233-238.
[42]Demyanets S, Kaun C, Rychli K, et al. Oncostatin m-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves pi3k-, p38 mapk-, erkl/2-and statl/stat3-dependent pathways and is attenuated by interferon-gamma [J]. Basic research in cardiology,2011,106(2):217-231.
[43]Smith DA, Kiba A, Zong Y, et al. Interleukin-6 and oncostatin-m synergize with the pi3k/akt pathway to promote aggressive prostate malignancy in mouse and human tissues [J]. Molecular cancer research: MCR,2013,11 (10):1159-1165.
[44]Savarese TM, Campbell CL, McQuain C, et al. Coexpression of oncostatin m and its receptors and evidence for stat3 activation in human ovarian carcinomas [J]. Cytokine,2002,17(6):324-334.
[45]A FWahl P. Oncostatin m in the anti-inflammatory response [J]. Ann Rheum Dis,2001,60(75-80.
[46]David E, Guihard P, Brounais B, et al. Direct anti-cancer effect of oncostatin m on chondrosarcoma [J]. International journal of cancer Journal international du cancer,2011,128(8):1822-1835.
[47]Queen MM, Ryan RE, Holzer RG, et al. Breast cancer cells stimulate neutrophils to produce oncostatin m:Potential implications for tumor progression [J]. Cancer research,2005,65(19):8896-8904.
[48]Garcia-Tunon I, Ricote M, Ruiz A, et al. Osm, lif, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative) [J]. Cancer investigation,2008,26(3):222-229.
[49]Begley SLGaCG. The oncostatin m signalling pathway:Reversing the neoplastic phenotype? [J]. MOLECULAR MEDICINE TODAY,1999,5(406-412.
[50]Bollrath J, Greten FR. Ikk/nf-kappab and stat3 pathways:Central signalling hubs in inflammation-mediated tumour promotion and metastasis [J]. EMBO reports,2009,10(12):1314-1319.
[51]Grivennikov SI, Karin M. Dangerous liaisons:Stat3 and nf-kappab collaboration and crosstalk in cancer [J]. Cytokine& growth factor reviews,2010,21 (1):11-19.
[52]Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification [J]. Acta Pathol Microbiol Scand,1965,64(31-49.
[53]Tanaka A, Takemura-Tsukashita S, Kushima R, et al. Low-grade gastric adenomas/dysplasias:Phenotypic expression, DNA ploidy pattern, and loh at microsatellites linked to the ape gene [J]. Pathology, research and practice,2008,204(1):1-9.
[54]Almeida R, Silva E, Santos-Silva F, et al. Expression of intestine-specific transcription factors, cdxl and cdx2, in intestinal metaplasia and gastric carcinomas [J]. The Journal of pathology, 2003,199(1):36-40.
[55]Machado JC, Oliveira C, Carvalho R, et al. E-cadherin gene (cdh1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma [J]. Oncogene,2001,20(12):1525-1528.
[56]You WC, Li JY, Blot WJ, et al. Evolution of precancerous lesions in a rural chinese population at high risk of gastric cancer [J]. International journal of cancer Journal international du cancer, 1999,83 (5):615-619.
[57]Correa P, Cuello C, Duque E. Carcinoma and intestinal metaplasia of the stomach in colombian migrants [J]. Journal of the National Cancer Institute,1970,44(2):297-306.
[58]Kobayashi K, Okamoto T, Takayama S, et al. Genetic instability in intestinal metaplasia is a frequent event leading to well-differentiated early adenocarcinoma of the stomach [J]. European journal of cancer,2000,36(9):1113-1119.
[59]Tava F, Luinetti 0, Ghigna MR, et al. Type or extension of intestinal metaplasia and immature/atypical "indefinite-for-dysplasia" lesions as predictors of gastric neoplasia [J]. Human pathology, 2006,37 (11):1489-1497.
[60]Naylor GM, Gotoda T, Dixon M, et al. Why does japan have a high incidence of gastric cancer? Comparison of gastritis between uk and japanese patients [J]. Gut,2006,55(11):1545-1552.
[61]Jonaitis L, Ivanauskas A, Janciauskas D, et al. Precancerous gastric conditions in high helicobacter pylori prevalence areas: Comparison between eastern european (lithuanian, latvian) and asian (taiwanese) patients [J]. Medicina (Kaunas, Lithuania),2007,43(8):623-629.
[62]de Vries AC, Haringsma J, de Vries RA, et al. The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia:A recommendation for routine practice [J]. Gastrointestinal endoscopy,2009,70(1):18-25.
[63]Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia:The padova international classification [J]. The American journal of surgical pathology,2000,24(2):167-176.
[64]The vienna classification of gastrointestinal [J].2000.
[65]Stolte M. The new vienna classification of epithelial neoplasia of the gastrointestinal tract:Advantages and disadvantages [J]. Virchows Archiv an international journal of pathology, 2003,442(2):99-106.
[66]Nishida T, Tsutsui S, Kato M, et al. Treatment strategy for gastric non-invasive intraepithelial neoplasia diagnosed by endoscopic biopsy [J]. World journal of gastrointestinal pathophysiology, 2011,2 (6):93-99.
[67]Lee CK, Chung IK, Lee SH, et al. Is endoscopic forceps biopsy enough for a definitive diagnosis of gastric epithelial neoplasia? [J]. Journal of gastroenterology and hepatology,2010,25(9):1507-1513.
[68]张游,令狐恩强,卢忠生,杜红,王向东,孟江云,王红斌.术前活检在胃黏膜病变内镜黏膜下剥离术治疗中的价值分析[J].中华消化内镜杂志,2012,29(2)：151-154.
[69]Wu W. Endoscopic features predictive of gastric cancer in superficial lesions with biopsy-proven high grade intraepithelial neoplasia [J]. World Journal of Gastroenterology,2009,15(4):489.
[70]Kim YJ, Park JC, Kim JH, et al. Histologic diagnosis based on forceps biopsy is not adequate for determining endoscopic treatment of gastric adenomatous lesions [J]. Endoscopy,2010,42(8):620-626.
[71]Cho SJ, Choi IJ, Kim CG, et al. Risk of high-grade dysplasia or carcinoma in gastric biopsy-proven low-grade dysplasia:An analysis using the vienna classification [J]. Endoscopy,2011,43(6):465-471.
[72]Sung HY, Cheung DY, Cho SH, et al. Polyps in the gastrointestinal tract:Discrepancy between endoscopic forceps biopsies and resected specimens [J]. European journal of gastroenterology& hepatology, 2009,21 (2):190-195.
[73]Kim MK, Jang JY, Kim JW, et al. Is lesion size an independent indication for endoscopic resection of biopsy-proven low-grade gastric dysplasia? [J]. Digestive diseases and sciences,2013.
[74]Won CS, Cho MY, Kim HS, et al. Upgrade of lesions initially diagnosed as low-grade gastric dysplasia upon forceps biopsy following endoscopic resection [J]. Gut and liver,2011,5(2):187-193.
[75]Park JS, Hong SJ, Han JP, et al. Early-stage gastric cancers represented as dysplasia in a previous forceps biopsy:The importance of clinical management [J]. Digestive and liver disease:official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,2013,45(2):170-175.
[76]Kim SI, Han HS, Kim JH, et al. What is the next step for gastric atypical epithelium on histological findings of endoscopic forceps biopsy? [J]. Digestive and liver disease:official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,2013,45(7):573-577.
[77]Lee H, Kim H, Shin SK, et al. The diagnostic role of endoscopic submucosal dissection for gastric lesions with indefinite pathology [J]. Scandinavian journal of gastroenterology,2012,47(8-9):1101-1107.
[78]Kuang RG, Kuang Y, Luo QF, et al. Expression and significance of musashi-1 in gastric cancer and precancerous lesions [J]. World journal of gastroenterology:WJG,2013,19(39):6637-6644.
[79]Leja M, Wex T, Malfertheiner P. Markers for gastric cancer premalignant lesions:Where do we go? [J]. Digestive diseases, 2012,30(3):268-276.
[80]Farinati F, Cardin R, Cassaro M, et al. Helicobacter pylori, inflammation, oxidative damage and gastric cancer:A morphological, biological and molecular pathway [J]. European journal of cancer prevention:the official journal of the European Cancer Prevention Organisation (ECP),2008,17(3):195-200.
[81]Milne AN, Sitarz R, Carvalho R, et al. Early onset gastric cancer: On the road to unraveling gastric carcinogenesis [J]. Current molecular medicine,2007,7 (1):15-28.
[82]Liu P, Zhang XY, Shao Y, et al. Microsatellite instability in gastric cancer and pre-cancerous lesions [J]. World journal of gastroenterology:WJG,2005,11 (31):4904-4907.
[83]Rugge M, Bersani G, Bertorelle R, et al. Microsatellite instability and gastric non-invasive neoplasia in a high risk population in cesena, italy [J]. Journal of clinical pathology, 2005,58 (8):805-810.
[84]Gonzalez CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer:Where we are and where we should go [J]. International journal of cancer Journal international du cancer, 2012,130(4):745-753.
[85]Correa P, Schneider BG. Etiology of gastric cancer:What is new? [J]. Cancer epidemiology, biomarkers& prevention:a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,2005,14(8):1865-1868.
[86]Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation [J]. Nature,2008,454(7203):436-444.
[87]Anagnostopoulos GK, Stefanou D, Arkoumani E, et al. Immunohistochemical expression of cell-cycle proteins in gastric precancerous lesions [J]. Journal of gastroenterology and hepatology, 2008,23 (4):626-631.
[88]Fusco N, Rocco EG, Del Conte C, et al. Her2 in gastric cancer:A digital image analysis in pre-neoplastic, primary and metastatic lesions [J]. Modern Pathology,2013,26(6):816-824.
[89]Okugawa T, Oshima T, Chen X, et al. Down-regulation of claudin-3 is associated with proliferative potential in early gastric cancers [J]. Digestive diseases and sciences,2012,57(6):1562-1567.
[90]Park DY, Srivastava A, Kim GH, et al. Cdx2 expression in the intestinal-type gastric epithelial neoplasia:Frequency and significance [J]. Modern Pathology,2009,23(1):54-61.
[91]Kim HS, Lee JS, Freund JN, et al. Cdx-2 homeobox gene expression in human gastric carcinoma and precursor lesions [J]. Journal of gastroenterology and hepatology,2006,21(2):438-442.
[92]Qin R, Wang NN, Chu J, et al. Expression and significance of homeodomain protein cdx2 in gastric carcinoma and precancerous lesions [J]. World journal of gastroenterology:WJG,2012,18(25):3296-3302.
[93]Huang W, Yang L, Liang S, et al. Aeg-1 is a target of perifosine and is over-expressed in gastric dysplasia and cancers [J]. Digestive diseases and sciences,2013,58(10):2873-2880.
[94]Katsha A, Soutto M, Sehdev V, et al. Aurora kinase a promotes inflammation and tumorigenesis in mice and human gastric neoplasia [J]. Gastroenterology,2013,145(6):1312-1322 e1311-1318.
[95]Xing YN, Yang X, Xu XY, et al. The altered expression of ing5 protein is involved in gastric carcinogenesis and subsequent progression [J]. Human pathology,2011,42(1):25-35.
[96]Lee WA. Alpha-methylacyl-coa-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach [J]. Oncology,2006,71(3-4):246-250.
[97]Zheng ZX, Sun Y, Bu ZD, et al. Intestinal stem cell marker lgr5 expression during gastric carcinogenesis [J]. World journal of gastroenterology:WJG,2013,19(46):8714-8721.
[98]Hong S. Connection between inflammation and carcinogenesis in gastrointestinal tract:Focus on tgf-β signaling [J]. World Journal of Gastroenterology,2010,16(17):2080.
[99]Mishra L, Katuri V, Evans S. The role of praja and elf in tgf-beta signaling and gastric cancer [J]. Cancer biology & therapy, 2005,4 (7):694-699.
[100]Kim SH, Lee SH, Choi YL, et al. Extensive alteration in the expression profiles of tgfb pathway signaling components and tp53 is observed along the gastric dysplasia-carcinoma sequence [J]. Histology and histopathology,2008,23(12):1439-1452.
[2]Dai M, Ren J, Li N, et al. [estimation and prediction on cancer related incidence and mortality in china,2008] [J]. Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi,2012,33(1):57-61.
[3]Ohta H, Noguchi Y, Takagi K, et al. Early gastric carcinoma with special reference to macroscopic classification [J]. Cancer, 1987,60 (5):1099-1106.
[4]Lazar D, Taban S, Dema A, et al. Gastric cancer:The correlation between the clinicopathological factors and patients'survival (i) [J]. Rom J Morphol Embryol,2009,50(1):41-50.
[5]Bosman FT, Carneiro F, Hruban RH, et al. Who classification of tumours of the digestive system [M]. World Health Organization,2010.
[6]Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (maps):Guideline from the european society of gastrointestinal endoscopy (esge), european helicobacter study group (ehsg), european society of pathology (esp), and the sociedade portuguesa de endoscopia digestiva (sped) [J]. Endoscopy,2012,44 (1):74-94.
[7]Shen L, Shan Y-S, Hu H-M, et al. Management of gastric cancer in asia:Resource-stratified guidelines [J]. The Lancet Oncology, 2013,14(12):e535-e547.
[8]Correa P. Human gastric carcinogenesis-a multistep and multifactorial process-1st american-cancer-society award lecture on cancer-epidemiology and prevention [J]. Cancer research, 1992,52 (24):6735-6740.
[9]Meining A, Morgner A, Miehlke S, et al. Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach:A reality or merely an hypothesis? [J]. Best Pract Res Cl Ga,2001,15(6):983-998.
[10]de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions:A nationwide cohort study in the netherlands [J]. Gastroenterology,2008,134(4):945-952.
[11]Uchida M, Tsukamoto Y, Uchida T, et al. Genomic profiling of gastric carcinoma in situ and adenomas by array-based comparative genomic hybridization [J]. The Journal of pathology,2010,221(1):96-105.
[12]Dixon MF. Gastrointestinal epithelial neoplasia:Vienna revisited [J]. Gut,2002,51(1):130-131.
[13]Rugge M, Capelle LG, Cappellesso R, et al. Precancerous lesions in the stomach:From biology to clinical patient management [J]. Best practice& research Clinical gastroenterology,2013,27(2):205-223.
[14]Hong L, Li S, Liu L, et al. The value of mg7-ag and cox-2 for predicting malignancy in gastric precancerous lesions [J]. Cell biology international,2010,34(9):873-876.
[15]Vecchi M, Nuciforo P, Romagnoli S, et al. Gene expression analysis of early and advanced gastric cancers [J]. Oncogene, 2007,26 (29):4284-4294.
[16]Li ML, Zhang JC, Li SG, et al. Characteristic gene expression profiles in the progression from normal gastric epithelial cells to moderate gastric epithelial dysplasia and to gastric cancer [J]. Chinese medical journal,2012,125(10):1777-1783.
[17]Association WM. World medical association declaration of helsinki ethical principles for medical research involving human subjects [J]. JAMA:the journal of the American Medical Association,2013.
[18]Yamada T, Lee P-H, Burns A, et al. G0s2, an early response gene, regulates quiescence in naive t cells [J]. The Journal of Immunology, 2011,186(104.110.
[19]Heckmann BL, Zhang X, Xie X, et al. The g0/g1 switch gene 2 (g0s2):Regulating metabolism and beyond [J]. Biochimica et biophysica acta,2013,1831 (2):276-281.
[20]Welch C, Santra MK, El-Assaad W, et al. Identification of a protein, g0s2, that lacks bcl-2 homology domains and interacts with and antagonizes bcl-2 [J]. Cancer research,2009,69(17):6782-6789.
[21]Heinrich P, Behrmann I, Haan S, et al. Principles of interleukin (il)-6-type cytokine signalling and its regulation [J]. Biochem J, 2003,374(1-20.
[22]Hanahan D, Weinberg RA. Hallmarks of cancer:The next generation [J]. Cell,2011,144(5):646-674.
[23]Jones RG, Thompson CB. Tumor suppressors and cell metabolism:A recipe for cancer growth [J]. Genes& development,2009,23(5):537-548.
[24]Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism [J]. Nature reviews Cancer,2011,11(2):85-95.
[25]Santos CR, Schulze A. Lipid metabolism in cancer [J]. The FEBS journal,2012,279(15):2610-2623.
[26]Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism:Current perspectives and future directions [J]. Cell death& disease, 2012,3(e248.
[27]Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting:Integrating immunity's roles in cancer suppression and promotion [J]. Science, 2011,331 (6024):1565-1570.
[28]Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer [J]. Annual review of immunology, 2011,29(235-271.
[29]Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation:A magic bullet? [J]. Science,2013,339(6117):286-291.
[30]Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer [J]. Cell,2010,140(6):883-899.
[31]Li Q, Verma IM. Nf-kappab regulation in the immune system [J]. Nature reviews Immunology,2002,2(10):725-734.
[32]Karin M, Greten FR. Nf-kappab:Linking inflammation and immunity to cancer development and progression [J]. Nature reviews Immunology, 2005,5(10):749-759.
[33]Naugler WE, Karin M. Nf-kappab and cancer-identifying targets and mechanisms [J]. Current opinion in genetics& development, 2008,18(1):19-26.
[34]Karin M. Nuclear factor-kappab in cancer development and progression [J]. Nature,2006,441(7092):431-436.
[35]Fucci A, Colangelo T, Votino C, et al. The role of peroxisome proliferator-activated receptors in the esophageal, gastric, and colorectal cancer [J]. PPAR research,2012,2012(242498.
[36]Zandbergen F, Mandard S, Escher P, et al. The g0/g1 switch gene 2 is a novel ppar target gene [J]. The Biochemical journal,2005,392(Pt 2)-.313-324.
[37]Kusakabe M, Kutomi T, Watanabe K, et al. Identification of g0s2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches [J]. International journal of cancer Journal international du cancer,2010,126(8):1895-1902.
[38]Nobuhiko Takahashi TO, Wataru Motomura, Yoshinori Fujimoto, Isao Kawabata, Yutaka Kohgo. Activation of ppar inhibits cell growth and induces apoptosis in human gastric cancer cells [J]. FEBS Letters, 1999,455(135-139.
[39]Schweiger M, Paar M, Eder C, et al. G0/g1 switch gene-2 regulates human adipocyte lipolysis by affecting activity and localization of adipose triglyceride lipase [J]. Journal of lipid research, 2012,53(11):2307-2317.
[40]Kusakabe M, Watanabe K, Emoto N, et al. Impact of DNA demethylation of the g0s2 gene on the transcription of g0s2 in squamous lung cancer cell lines with or without nuclear receptor agonists [J]. Biochemical and biophysical research communications,2009,390(4):1283-1287.
[41]Das SK, Eder S, Schauer S, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia [J]. Science, 2011,333(6039):233-238.
[42]Demyanets S, Kaun C, Rychli K, et al. Oncostatin m-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves pi3k-, p38 mapk-, erkl/2-and statl/stat3-dependent pathways and is attenuated by interferon-gamma [J]. Basic research in cardiology,2011,106(2):217-231.
[43]Smith DA, Kiba A, Zong Y, et al. Interleukin-6 and oncostatin-m synergize with the pi3k/akt pathway to promote aggressive prostate malignancy in mouse and human tissues [J]. Molecular cancer research: MCR,2013,11 (10):1159-1165.
[44]Savarese TM, Campbell CL, McQuain C, et al. Coexpression of oncostatin m and its receptors and evidence for stat3 activation in human ovarian carcinomas [J]. Cytokine,2002,17(6):324-334.
[45]A FWahl P. Oncostatin m in the anti-inflammatory response [J]. Ann Rheum Dis,2001,60(75-80.
[46]David E, Guihard P, Brounais B, et al. Direct anti-cancer effect of oncostatin m on chondrosarcoma [J]. International journal of cancer Journal international du cancer,2011,128(8):1822-1835.
[47]Queen MM, Ryan RE, Holzer RG, et al. Breast cancer cells stimulate neutrophils to produce oncostatin m:Potential implications for tumor progression [J]. Cancer research,2005,65(19):8896-8904.
[48]Garcia-Tunon I, Ricote M, Ruiz A, et al. Osm, lif, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative) [J]. Cancer investigation,2008,26(3):222-229.
[49]Begley SLGaCG. The oncostatin m signalling pathway:Reversing the neoplastic phenotype? [J]. MOLECULAR MEDICINE TODAY,1999,5(406-412.
[50]Bollrath J, Greten FR. Ikk/nf-kappab and stat3 pathways:Central signalling hubs in inflammation-mediated tumour promotion and metastasis [J]. EMBO reports,2009,10(12):1314-1319.
[51]Grivennikov SI, Karin M. Dangerous liaisons:Stat3 and nf-kappab collaboration and crosstalk in cancer [J]. Cytokine& growth factor reviews,2010,21 (1):11-19.
[52]Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification [J]. Acta Pathol Microbiol Scand,1965,64(31-49.
[53]Tanaka A, Takemura-Tsukashita S, Kushima R, et al. Low-grade gastric adenomas/dysplasias:Phenotypic expression, DNA ploidy pattern, and loh at microsatellites linked to the ape gene [J]. Pathology, research and practice,2008,204(1):1-9.
[54]Almeida R, Silva E, Santos-Silva F, et al. Expression of intestine-specific transcription factors, cdxl and cdx2, in intestinal metaplasia and gastric carcinomas [J]. The Journal of pathology, 2003,199(1):36-40.
[55]Machado JC, Oliveira C, Carvalho R, et al. E-cadherin gene (cdh1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma [J]. Oncogene,2001,20(12):1525-1528.
[56]You WC, Li JY, Blot WJ, et al. Evolution of precancerous lesions in a rural chinese population at high risk of gastric cancer [J]. International journal of cancer Journal international du cancer, 1999,83 (5):615-619.
[57]Correa P, Cuello C, Duque E. Carcinoma and intestinal metaplasia of the stomach in colombian migrants [J]. Journal of the National Cancer Institute,1970,44(2):297-306.
[58]Kobayashi K, Okamoto T, Takayama S, et al. Genetic instability in intestinal metaplasia is a frequent event leading to well-differentiated early adenocarcinoma of the stomach [J]. European journal of cancer,2000,36(9):1113-1119.
[59]Tava F, Luinetti 0, Ghigna MR, et al. Type or extension of intestinal metaplasia and immature/atypical "indefinite-for-dysplasia" lesions as predictors of gastric neoplasia [J]. Human pathology, 2006,37 (11):1489-1497.
[60]Naylor GM, Gotoda T, Dixon M, et al. Why does japan have a high incidence of gastric cancer? Comparison of gastritis between uk and japanese patients [J]. Gut,2006,55(11):1545-1552.
[61]Jonaitis L, Ivanauskas A, Janciauskas D, et al. Precancerous gastric conditions in high helicobacter pylori prevalence areas: Comparison between eastern european (lithuanian, latvian) and asian (taiwanese) patients [J]. Medicina (Kaunas, Lithuania),2007,43(8):623-629.
[62]de Vries AC, Haringsma J, de Vries RA, et al. The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia:A recommendation for routine practice [J]. Gastrointestinal endoscopy,2009,70(1):18-25.
[63]Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia:The padova international classification [J]. The American journal of surgical pathology,2000,24(2):167-176.
[64]The vienna classification of gastrointestinal [J].2000.
[65]Stolte M. The new vienna classification of epithelial neoplasia of the gastrointestinal tract:Advantages and disadvantages [J]. Virchows Archiv an international journal of pathology, 2003,442(2):99-106.
[66]Nishida T, Tsutsui S, Kato M, et al. Treatment strategy for gastric non-invasive intraepithelial neoplasia diagnosed by endoscopic biopsy [J]. World journal of gastrointestinal pathophysiology, 2011,2 (6):93-99.
[67]Lee CK, Chung IK, Lee SH, et al. Is endoscopic forceps biopsy enough for a definitive diagnosis of gastric epithelial neoplasia? [J]. Journal of gastroenterology and hepatology,2010,25(9):1507-1513.
[68]张游,令狐恩强,卢忠生,杜红,王向东,孟江云,王红斌.术前活检在胃黏膜病变内镜黏膜下剥离术治疗中的价值分析[J].中华消化内镜杂志,2012,29(2)：151-154.
[69]Wu W. Endoscopic features predictive of gastric cancer in superficial lesions with biopsy-proven high grade intraepithelial neoplasia [J]. World Journal of Gastroenterology,2009,15(4):489.
[70]Kim YJ, Park JC, Kim JH, et al. Histologic diagnosis based on forceps biopsy is not adequate for determining endoscopic treatment of gastric adenomatous lesions [J]. Endoscopy,2010,42(8):620-626.
[71]Cho SJ, Choi IJ, Kim CG, et al. Risk of high-grade dysplasia or carcinoma in gastric biopsy-proven low-grade dysplasia:An analysis using the vienna classification [J]. Endoscopy,2011,43(6):465-471.
[72]Sung HY, Cheung DY, Cho SH, et al. Polyps in the gastrointestinal tract:Discrepancy between endoscopic forceps biopsies and resected specimens [J]. European journal of gastroenterology& hepatology, 2009,21 (2):190-195.
[73]Kim MK, Jang JY, Kim JW, et al. Is lesion size an independent indication for endoscopic resection of biopsy-proven low-grade gastric dysplasia? [J]. Digestive diseases and sciences,2013.
[74]Won CS, Cho MY, Kim HS, et al. Upgrade of lesions initially diagnosed as low-grade gastric dysplasia upon forceps biopsy following endoscopic resection [J]. Gut and liver,2011,5(2):187-193.
[75]Park JS, Hong SJ, Han JP, et al. Early-stage gastric cancers represented as dysplasia in a previous forceps biopsy:The importance of clinical management [J]. Digestive and liver disease:official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,2013,45(2):170-175.
[76]Kim SI, Han HS, Kim JH, et al. What is the next step for gastric atypical epithelium on histological findings of endoscopic forceps biopsy? [J]. Digestive and liver disease:official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,2013,45(7):573-577.
[77]Lee H, Kim H, Shin SK, et al. The diagnostic role of endoscopic submucosal dissection for gastric lesions with indefinite pathology [J]. Scandinavian journal of gastroenterology,2012,47(8-9):1101-1107.
[78]Kuang RG, Kuang Y, Luo QF, et al. Expression and significance of musashi-1 in gastric cancer and precancerous lesions [J]. World journal of gastroenterology:WJG,2013,19(39):6637-6644.
[79]Leja M, Wex T, Malfertheiner P. Markers for gastric cancer premalignant lesions:Where do we go? [J]. Digestive diseases, 2012,30(3):268-276.
[80]Farinati F, Cardin R, Cassaro M, et al. Helicobacter pylori, inflammation, oxidative damage and gastric cancer:A morphological, biological and molecular pathway [J]. European journal of cancer prevention:the official journal of the European Cancer Prevention Organisation (ECP),2008,17(3):195-200.
[81]Milne AN, Sitarz R, Carvalho R, et al. Early onset gastric cancer: On the road to unraveling gastric carcinogenesis [J]. Current molecular medicine,2007,7 (1):15-28.
[82]Liu P, Zhang XY, Shao Y, et al. Microsatellite instability in gastric cancer and pre-cancerous lesions [J]. World journal of gastroenterology:WJG,2005,11 (31):4904-4907.
[83]Rugge M, Bersani G, Bertorelle R, et al. Microsatellite instability and gastric non-invasive neoplasia in a high risk population in cesena, italy [J]. Journal of clinical pathology, 2005,58 (8):805-810.
[84]Gonzalez CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer:Where we are and where we should go [J]. International journal of cancer Journal international du cancer, 2012,130(4):745-753.
[85]Correa P, Schneider BG. Etiology of gastric cancer:What is new? [J]. Cancer epidemiology, biomarkers& prevention:a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,2005,14(8):1865-1868.
[86]Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation [J]. Nature,2008,454(7203):436-444.
[87]Anagnostopoulos GK, Stefanou D, Arkoumani E, et al. Immunohistochemical expression of cell-cycle proteins in gastric precancerous lesions [J]. Journal of gastroenterology and hepatology, 2008,23 (4):626-631.
[88]Fusco N, Rocco EG, Del Conte C, et al. Her2 in gastric cancer:A digital image analysis in pre-neoplastic, primary and metastatic lesions [J]. Modern Pathology,2013,26(6):816-824.
[89]Okugawa T, Oshima T, Chen X, et al. Down-regulation of claudin-3 is associated with proliferative potential in early gastric cancers [J]. Digestive diseases and sciences,2012,57(6):1562-1567.
[90]Park DY, Srivastava A, Kim GH, et al. Cdx2 expression in the intestinal-type gastric epithelial neoplasia:Frequency and significance [J]. Modern Pathology,2009,23(1):54-61.
[91]Kim HS, Lee JS, Freund JN, et al. Cdx-2 homeobox gene expression in human gastric carcinoma and precursor lesions [J]. Journal of gastroenterology and hepatology,2006,21(2):438-442.
[92]Qin R, Wang NN, Chu J, et al. Expression and significance of homeodomain protein cdx2 in gastric carcinoma and precancerous lesions [J]. World journal of gastroenterology:WJG,2012,18(25):3296-3302.
[93]Huang W, Yang L, Liang S, et al. Aeg-1 is a target of perifosine and is over-expressed in gastric dysplasia and cancers [J]. Digestive diseases and sciences,2013,58(10):2873-2880.
[94]Katsha A, Soutto M, Sehdev V, et al. Aurora kinase a promotes inflammation and tumorigenesis in mice and human gastric neoplasia [J]. Gastroenterology,2013,145(6):1312-1322 e1311-1318.
[95]Xing YN, Yang X, Xu XY, et al. The altered expression of ing5 protein is involved in gastric carcinogenesis and subsequent progression [J]. Human pathology,2011,42(1):25-35.
[96]Lee WA. Alpha-methylacyl-coa-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach [J]. Oncology,2006,71(3-4):246-250.
[97]Zheng ZX, Sun Y, Bu ZD, et al. Intestinal stem cell marker lgr5 expression during gastric carcinogenesis [J]. World journal of gastroenterology:WJG,2013,19(46):8714-8721.
[98]Hong S. Connection between inflammation and carcinogenesis in gastrointestinal tract:Focus on tgf-β signaling [J]. World Journal of Gastroenterology,2010,16(17):2080.
[99]Mishra L, Katuri V, Evans S. The role of praja and elf in tgf-beta signaling and gastric cancer [J]. Cancer biology & therapy, 2005,4 (7):694-699.
[100]Kim SH, Lee SH, Choi YL, et al. Extensive alteration in the expression profiles of tgfb pathway signaling components and tp53 is observed along the gastric dysplasia-carcinoma sequence [J]. Histology and histopathology,2008,23(12):1439-1452.